CTLA4 and neoplasm: On the other hand, multiple studies have indicated that high expression of PD-1/PD-L1 or CTLA-4 in the PDAC tumor microenvironment is associated with a worse outcome, suggesting that targeting CTLA-4 or the PD-1/PD-L1 interaction may yield therapeutic benefit [70–72].